Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Huayang New Material Technology Group Co. Lt is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter represents the company's current focus at the USPTO. The case is assigned to 1 distinct examiner, which allows for a direct and focused dialogue between the applicant and the examiner.
The prosecution is situated within 1 distinct art unit. This indicates that the technology is highly specialized within the biotechnology sector. Because the portfolio is limited to 1 distinct art unit, the practitioner can focus on the specific examination standards and precedents relevant to that particular department.
MURESAN, ANA Z is the busiest examiner for the portfolio, currently responsible for 1 busiest examiner pending action. As the sole examiner involved in the company's current prosecution, MURESAN, ANA Z will have a significant impact on the eventual outcome of the claims. Understanding the specific examination style of MURESAN, ANA Z is critical.
With 1 pending office action, the prosecution strategy is focused on a single set of requirements. The practitioner can devote resources to addressing the specific concerns raised in the Biotechnology & Pharmaceuticals area. This environment allows for a targeted response to the office action issued by the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MURESAN, ANA Z | 1 | 75.0% | +31.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610458 | KETTLE-TYPE CONTINUOUS PRODUCTION METHOD FOR GLYCINE | MURESAN, ANA Z | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17610458 | KETTLE-TYPE CONTINUOUS PRODUCTION METHOD FOR GLYCINE | MURESAN, ANA Z | 1692 | §103 | Non-Final OA | — | Pending | Sep 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuayang New Material Technology Group Co. Lt has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ana Z Muresan has the most, with 1 of Huayang New Material Technology Group Co. Lt's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
